

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

NCT06508775

Status	RECRUITING
Phase	Not Applicable
Sponsor	Miltenyi Biomedicine GmbH
Enrollment	40 participants

Plain Language Summary

This study is conducting long-term safety follow-up for patients who previously received a CAR T-cell therapy (a type of immune cell cancer treatment) made by Miltenyi Biotec in a prior clinical trial. The goal is to monitor patients for at least 15 years to check for any delayed or long-term side effects.

****You may be eligible if...****

- You previously received a Miltenyi CAR T-cell therapy as part of a clinical trial at least 12 months ago
- You are able to provide informed consent to participate in follow-up

****You may NOT be eligible if...****

- There are no exclusion criteria for this long-term follow-up study

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (2)

- Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.
- Patient has provided informed consent prior to enrollment.

Locations (7 total)

Uniklinikum Erlangen, Erlangen, Germany
Universitätsmedizin Göttingen, Göttingen, Germany
Universitätsklinikum Münster, Münster, Germany
... and 4 more locations

<https://clinicaltrials.gov/study/NCT06508775>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).